Search results
Results from the WOW.Com Content Network
Ropeginterferon alfa-2b can cause liver enzyme elevations, low levels of white blood cells, low levels of platelets, joint pain, fatigue, itching, upper airway infection, muscle pain and flu-like illness. [3] Side effects may also include urinary tract infection, depression and transient ischemic attacks (stroke-like attacks). [3]
Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli [ 1 ] in the laboratory of Charles Weissmann at the University of Zurich , in 1980.
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. [3] Also used to treat hepatitis C (typically, in combination with ribavarin), it is no longer recommended due to poor efficacy and adverse side-effects. [4] Subcutaneous injection is the preferred delivery method. [3]
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now.
Interferon alfa is used in a ... Common side effects (≥10% ... injection site reactions, fatigue, flu-like symptoms; loss of appetite and weight loss. ...
The interferon-α/β receptor (IFNAR) is a virtually ubiquitous membrane receptor which binds endogenous type I interferon (IFN) cytokines. Endogenous human type I IFNs include many subtypes, such as interferons-α, -β, -ε, -κ, -ω, and -ζ.
It’s also associated with appetite suppression and increased feelings of fullness, which may lead to reduced food intake and weight loss. ... there isn’t as much data on the long-term effects ...
Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012: [1] Pegylated interferon-alpha-2a; Pegylated interferon-alpha-2b; Pegylated interferon beta-1a [2] In these formulations, Polyethylene glycol (PEG) is added to make interferon last longer in the body. [3]